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Abstract: The initial step in retroviral infection involves specific interactions between viral 
envelope proteins (Env) and specific receptors on the surface of target cells. For many 
years, little was known about the entry receptors for HTLV-1. During this time, however, 
functional  domains  of  the  HTLV-1  Env  were  identified  by  analyzing  the  effects  of 
neutralizing antibodies and specific mutations in Env on HTLV-1 infectivity. More recent 
studies have revealed that HTLV-1 infectivity involves interactions with three different 
molecules: heparan sulfate proteoglycans (HSPG), the VEGF-165 receptor Neuropilin 1 
(NRP-1) and glucose transporter type 1 (GLUT1). Here, we revisit previously published 
data on the functional domains of Env in regard to the recent knowledge acquired about 
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this  multi-receptor  complex.  We  also  discuss  the  similarities  and  differences  between 
HTLV-1 and other deltaretroviruses in regards to receptor usage. 
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1. Introduction  
Like other enveloped viruses, retroviruses enter target cells by fusing their membrane with the 
membrane of target cells. This process is initiated by interaction of the surface subunit (SU) of the 
virally-encoded envelope glycoprotein (Env) with host cell receptors. Data from several independent 
groups  have  determined  that  three  cell  surface  proteins  are  involved  in  HTLV-1  entry:  glucose 
transporter  1  (GLUT1),  neuropilin-1  (NRP-1)  and  heparan  sulfate  proteoglycans  (HSPG).  This 
knowledge  provides  a  new  perspective  on  HTLV-1  tropism  and  associated  pathologies.  This  also 
raises  many  questions  about  the  molecular  events  that  occur  during  entry,  in  particular  how  the  
HTLV-1  SU  interacts  with  each  of  the  receptor  molecules.  The  impact  of  the  receptors  on  the 
selectivity and modulation of HTLV-1 infection in vivo has been recently reviewed in detail [1,2]. In 
this review, we reexamine what is known from earlier studies about the functional domains of Env in 
light of the recent insight into the receptor complex. We will also present recent data obtained with the 
other members of the HTLV family and discuss their implications in terms of receptor usage.  
2. The Host Cell Actors: The HTLV-1 Receptors  
Here, we will only briefly summarize the evidence that identified the HTLV-1 receptor molecules 
and led to the proposal of a multi-receptor model for HTLV-1 entry.  
2.1. Identification of the Roles of GLUT1, NRP-1 and HSPGs in HTLV-1 Entry 
The identification of GLUT1 started with the observation that expression of a fragment of the 
HTLV-1 SU in cells prevents medium acidification [3]. Since it is known for other retroviruses that SU 
interacts with their receptors when coexpressed in cells, the authors hypothesized that the HTLV-1 
receptor might be related to proton-dependent lactate production. Investigation of different members of 
the glucose transporter family led to the observation that one of these, GLUT1, was indeed able to bind 
the SU and promote HTLV-1-Env mediated particle entry. The same study showed that the residues 
D106 and Y114 of the SU were involved in GLUT1 binding [3]. A subsequent study from another 
group demonstrated that GLUT1 is required for HTLV-1 infection of CD4
+ T cells [4].  
In parallel, the role in HTLV-1 entry of another protein, Neuropilin 1 (NRP-1), was investigated. 
NRP-1  is  a  cell  surface  protein  known  to  function  as  a  co-receptor  for  certain  heparin-binding  
pro-angiogenic  cytokines,  principally  members  of  the  vascular  endothelial  growth  factor  (VEGF) 
family, and for class 3 semaphorins (reviewed in [5]). It was noticed that a number of features of  
NRP-1 paralleled characteristics of the HTLV-1 receptor, including a high degree of conservation 
among vertebrate species [6], the absence of a homolog in the Drosophila genome, overexpression in 
transformed cells [7] and upregulation upon T-cell activation [8]. It was subsequently demonstrated Viruses 2011, 3                         
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that  NRP-1  binds  HTLV-1  SU  and  is  required  for  efficient  HTLV-1  entry.  The  same  study  also 
showed that NRP-1, GLUT1 and the HTLV-1 SU form a stable tripartite complex when coexpressed 
in cells [9].  
The role of the third player of HTLV-1 entry, HSPGs, was the first of the three molecules identified 
to be important for HTLV-1 entry, through experiments showing that removal of HSPGs from cell 
surface abolished binding of the HTLV-1 SU as well as HTLV-1-Env mediated infection of target  
cells  [10].  Later  studies  showed  that  HSPGs  were  also  required  for  efficient  HTLV-1  entry  into 
primary T cells and dendritic cells [11,12]. The region of the SU involved in HSPG binding was 
characterized using the fact that, unlike HTLV-1, binding of the HTLV-2 SU to target cells does not 
depend on HSPGs. Analysis of various HTLV-1/HTLV-2 SU chimera demonstrated that binding to 
HSPGs involved the C-terminal domain of the HTLV-1 SU (amino-acids 215–313) [13]. 
2.2. Cooperation between the HTLV-1 Receptors 
The fact that NRP-1 and GLUT1 can form a complex in the presence of HTLV-1 Env suggested 
that these two molecules work together to promote HTLV-1 entry. Such cooperation was also recently 
functionally demonstrated by data showing that inhibition of HTLV-1 entry into primary astrocytes 
required the blocking of the interactions with both NRP-1 and GLUT1 [14]. 
Previously, HSPGs and NRP-1 have been shown to cooperate while functioning as co-receptors for 
the pro-angiogenic factor VEGF-165. Initial binding to cells is believed to involve interactions of 
VEGF-165 with both NRP-1 and heparin sulfate (HS) chains, followed by interaction of VEGF-165 
with its signaling receptor VEGF-R [15]. Structural and functional studies indicate that VEGF-165 
directly  binds  to  both  NRP-1  and  heparin,  and  that  NRP-1  and  heparin  also  directly  bind  to  one 
another, allowing VEGF-165 dimerization and stable binding on cells [16]. The regions of VEGF-165 
responsible for binding heparin and NRP-1 map to exon 7 and exon 8, respectively, with three residues 
in exon 8 (KPxR) critical for direct NRP-1 binding to VEGF-165 [16] (Figure 1). 
Recently, it has been shown that HSPG and NRP-1 also work together to promote HTLV-1 Env 
binding. Indeed, like VEGF-165, HTLV-1 SU binds via a HS-dependent manner to the same domain 
of NRP-1 important for binding VEGF-165 (NRP-1 b domain, see Figures 1 and 2). Moreover, it was 
discovered that the same KPxR motif critical for direct binding of VEGF-165 exon 8 to NRP-1 was 
present in the SU of HTLV-1, in a region previously shown to be important for infectivity (Figures 1B 
and 3). Further studies revealed that a pentapeptide corresponding to the region of the HTLV-1 SU 
encoding this motif (aa 90–94, KKPNR) directly binds to NRP-1 in vitro and was sufficient to block 
HTLV-1 entry into primary T or dendritic cells [17]. Thus, the HTLV-1 SU stably binds to NRP-1 
through both HSPG-mediated and direct interactions by mimicking the NRP-1 ligand VEGF-165.  
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Figure 1. (A) Schematic representation of the binding of VEGF-165 to heparan sulfate 
proteoglycans (HSPG)/neuropilin-1 (NRP-1) complexes prior to interaction with the VEGF 
receptor.  The  position  in  VEGF-165  of  the  exon  7-encoded  sequence,  which  binds  to 
HSPGs, is indicated. The primary amino acid sequence of the exon 8-encoded sequence, 
which directly binds to the b domain of NRP-1, is also shown. The a, b and c domains of 
NRP-1 are painted in red, green or yellow, respectively. (B) Homology between the exon 
8-encoded domain of VEGF-165 and the amino acid 90-94 region of the HTLV-1 surface 
subunit (SU).  
 
2.3. A Multireceptor Model for HTLV-1 Entry 
The data described above support a multi-receptor model for HTLV-1 entry that involves three 
phases: virus attachment, virus binding and virus/cell fusion (recently discussed in [2]) (Figure 2). 
Virus attachment is mediated through interaction of the SU with the HS chains, most likely on cell 
surface HSPG. Then, because HS chains are able to interact with NRP-1, prior binding of the SU to 
HSPGs increases the probability of the SU to encounter NRP-1 and allows stable binding to NRP-1, 
ensuring thereby the transition between virus attachment and virus binding. This binding of the SU to 
HSPG/NRP-1  complexes  allows  exposure  of  the  GLUT1-binding  domain,  presumably  via 
conformational changes. Finally, the SU binds to GLUT1, triggering the fusion process that allows 
entry of the HTLV-1 core in the cell cytoplasm.  
The notion that HSPG/NRP-1 are important for the initial binding step is supported by previous 
observations that HTLV-1 SU and particle binding are dramatically reduced following removal of HS 
chains or upon blocking NRP-1 interactions by incubation of target cells with either VEGF-165 exon 7 
or  exon  8-like  peptides  [12,17].  Blocking  interactions  with  HS  chains  and  NRP-1  also  decreased 
infection of CD4
+ T cells by HTLV-1 [11]. Previous studies indicate that at least some of the HS 
chains are in the form of HSPGs, likely with syndecans as core proteins [13]. However, since NRP-1 
itself is modified by HS on certain cell types [18], it leaves two possibilities for SU binding; the SU Viruses 2011, 3                         
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binds to HSPGs which interact with NRP-1 or the SU interacts directly with HS conjugated to NRP-1. 
A role of GLUT1 in the fusion step subsequent to the initial binding is supported by the observation 
that  the  level  of  GLUT1  expression  on  target  cells  correlates  with  the  titer  of  HTLV-1  
Env-pseudotyped viruses but not with the level of binding of the HTLV-1 viral particle or soluble full 
length HTLV-1 SU protein [3,13,14,19].  
Figure  2.  A  multireceptor  model  for  HTLV-1  entry.  HSPGs,  NRP-1  and  GLUT1 
expressed on the surface of target cells work together to promote HTLV-1 entry. Step 1: 
The HTLV-1 SU interacts with HSPGs via its C-terminal domain (CTD), which allows the 
initial attachment and concentration of HTLV-1 particles at the cell surface, Step 2: HSPGs 
interaction with both the SU and NRP-1 as well as direct binding of the SU to the b domain 
of  NRP-1  via  the  90–94  domain  allow  the  recruitment  of  NRP-1;  Step  3:  The  stable 
binding of the SU to HSPGs/NRP-1 complexes triggers conformational changes within the 
SU  allowing  GLUT1  binding,  notably  via  residues  D106  and  Y114  of  the  SU.  The  
HTLV-1 SU is represented in blue with its three modules: the Receptor-Binding domain 
(RBD), the Proline-Rich Region (PRR) and the C-terminal domain (CTD). The black box 
within  the  RBD  represents  the  88–120  region  that  contains  the  KPxR  motif  and  the 
D106/Y114 residues responsible for NRP-1 or GLUT1 binding, respectively. 
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3. The Viral Actor: The HTLV-1 SU Protein  
3.1. Function of Retroviral SU Proteins  
Retroviral  envelope  glycoproteins  (Env)  are  type-I  transmembrane  proteins  synthesized  as  a 
precursor that is co-translationally imported into the endoplasmic reticulum, where it subsequently 
undergoes  a  number  of  maturation  steps,  including  folding,  oligomerization  and  N-glycosylations. 
Upon completion of these processes, the Env precursor passes through the Golgi apparatus to the trans 
golgi network, where it is cleaved by a cellular protease of the furin family into SU (Surface) and TM 
(Transmembrane) subunits [20]. SU-TM complexes organized as trimers are then transported to the 
surface of infected cells, where incorporation into the budding particles occurs [21]. 
Retrovirus entry occurs by fusion of the viral envelope either with the cell plasma membrane [22], 
or with endosomal membranes following internalization via a endocytic pathway [23–25]. In both 
cases,  the  entry  process  per  se  occurs  through  an  initial  binding  step  mediated  by  the  SU  and  a 
subsequent  fusion  step  mediated  by  the  TM.  Accordingly,  the  SU  contains  the  determinants  for 
receptor binding and the TM has the hydrophobic fusogenic peptide in its N-terminal region. During 
the  intracellular  journey  of  SU/TM  complexes  and  prior  to  contact  with  the  receptor,  the  TM  is 
maintained by close association with the SU in a fusogenic-inactive metastable conformation in which 
the  fusion  peptide  is  buried.  This  prevents  premature  membrane  fusion  that  could  lead  to  Env 
inactivation and cell toxicity. The key event for TM activation is alteration of the SU/TM interactions, 
which allows the TM to acquire its fusogenic state. In the case of murine leukemia virus (MLV) Env, 
SU/TM dissociation is triggered upon binding of the SU to its receptor mCAT-1 and relies on the 
disruption of an intersubunit disulfite bond between cysteines in a CxxC motif in the SU and a CX6CC 
motif in the TM [26,27]. For human immunodeficiency virus type 1 (HIV-1) Env, TM activation 
requires  successive  contacts  with  two  entry  receptors,  the  primary  binding  receptor  CD4  and  the  
co-receptor  (CXCR4  or  CCR5),  with  the  latter  contact  triggering  SU/TM  dissociation  [28].  The 
conformational  changes  required  for  chemokine  binding  are  also  facilitated  by  thiol/disulfide 
rearrangement  in  the  SU-gp120,  which  involves  gp120  binding  to  cell  surface  protein  disulfite 
isomerase [29].  
For all retroviruses, final activation of the fusion process occurs through successive refolding events 
of the TM resulting in the projection of the N-terminal fusion peptide. This involves the formation of a 
six-helix coiled-coil bundle that brings the viral and target membranes in close proximity and triggers 
membrane fusion. Since this review is focused on the interactions between the SU subunit and the  
cell  receptors,  details  of  these  processes  will  not  be  described  here  but  can  be  found  in  recent  
reviews [22,30]. 
3.2. General Organization of the HTLV-1 SU 
The HTLV-1 env gene encodes a 488 amino acid precursor protein, which generates a 62 kDa 
protein (gp62) after addition of five N-glycan chains, four of which are in the SU (Figure 3) [31]. The 
gp62 is cleaved at a trypsin-like proteolytic site spanning residues 309–312 into the mature SU (gp46) 
and TM (gp21) subunits [31]. The SU is entirely extracellular and remains linked to the virus through 
binding to the TM, which is embedded in the viral envelope. Viruses 2011, 3                         
 
 
800 
No direct structural data are available for the HTLV-1 SU. However, structural domains have been 
predicted  based  on  sequence  homology  with  SU  proteins  of  gammaretroviruses.  Structural  and 
functional studies of MLV Env revealed that the SU is organized into three structural modules: an  
N-terminal receptor binding  domain (RBD)  and a  C-terminal  domain (CTD)  separated by a short 
proline-rich  region  (PRR)  [32–34].  Alignment  of  the  amino  acid  sequences  of  the  HTLV-1  and  
Friend-MLV SU predicted that the  HTLV-1  SU is  similarly  organized,  beginning after the signal 
peptide (residues 1–25), with an N-terminal region (26–180), a Proline-Rich Region (181–215) and a 
C-terminal domain (216-312) [35,36] (Figure 3). Analysis of MLV/SU chimeras demonstrated that the 
N-terminal domain of the HTLV-1 SU can complement the MLV RBD and confer HTLV-1 tropism to 
the resulting protein, indicating that the HTLV-1 residues important for receptor interactions  map 
within  the predicted  HTLV-1  RBD  [36].  Later  studies  with  a  soluble  form  of  the  HTLV-1  RBD 
revealed that this domain is sufficient for binding to the cell surface of target cells [36]. However, 
binding experiments performed with the full length HTLV-1 SU further demonstrated that regions 
outside the RBD contain important determinants for SU binding to target cells [13]. Residues outside 
the  RBD  have  also  been  shown  to  encode  viral  entry  determinants  for  several  different 
gammaretroviruses [37,38]. 
In gammaretroviruses, the PRR domain is believed to represent a hinge region that facilitates the 
conformational changes induced by receptor binding  [32]. The HTLV-1 SU PRR region has been 
shown to complement the homologous domain of MLV SU [35], suggesting that it plays a similar role 
in HTLV-1 SU refolding. The CTD of HTLV-1 SU contains a typical disulfide isomerization motif 
(CxxC;  residues  225  to  228,  see  Figure  3)  homologous  to  the  motif  in  MLV  important  for 
conformational changes required for fusion that occur after receptor binding. Mutation of C225 blocks 
HTLV-1  Env-mediated  infection  and  cell-cell  fusion,  but  dithiothreitol  reverses  this  effect.  This 
indicates that the thiol of this residue is responsible for the disulfite isomerization that occurs following 
receptor binding, thus disrupting the SU-TM bond and allowing fusion mediated by the TM [39]. The 
Ser residue at position 101 also controls SU/TM association [40] (Figure 3). Details of the mechanism 
of HTLV-1 gp41-mediated fusion have been described elsewhere [41,42]. 
3.3. Functional Residues of the HTLV-1 SU 
One approach to identifying functional domains of retroviral envelope proteins, notably the receptor 
binding determinants, is to identify the epitopes of neutralizing antibodies which block Env-mediated 
functions. In the case of HTLV-1, analysis of the specificities of anti-HTLV-1 neutralizing antibodies 
identified four functional regions in the SU: two N-terminal regions located between residues 53–75 
and 86–107 [43,45], a central region located between residues 175-199 [46,47] and a C-terminal one 
located between residues 287–311 [45] (also reviewed in [48]) (Figure 3).  
The  86–107  region  was  initially  mapped  from  antibodies  raised  against  HTLV-1  peptides 
corresponding  to  regions  of  the  SU  predicted  to  be  hydrophilic.  Adsorption  of  the  neutralizing 
activities using a set of shorter peptides identified six residues (KKPNRN) at position 90 to 95 as the 
minimal neutralizing epitope in this domain [43] (Figure 3). Previous analysis of mutants carrying 
single amino acid changes in HTLV-1 SU identified two residues in this region critical for cell-cell 
transmission of the virus: one (R94) which maps in the minimal neutralizing epitope and another in the Viruses 2011, 3                         
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larger (S101) [44]. The central 175–199 region overlaps with the PRR, which has been shown for 
gammaretroviruses to mediate the SU refolding events that occur following binding to the receptor, 
resulting in activation of fusion by the TM. The observation that the MLV TM can become fusogenic 
when present on a chimeric molecule with the HTLV RBD and PRR indicates that the HTLV PRR 
also functions to transmit the signal from the RBD to the CTD [36].  
Figure 3. Localization of the neutralizing regions and the domains and residues involved in 
HSPGs, NRP-1 and GLUT1 binding within the HTLV-1 SU. The 90-94 motif identified as 
critical for direct NRP-1 binding [17] corresponds to a minimal neutralizing epitope [43], 
and contains the R94 residue required for HTLV-1 particle infectivity [44]. R94, as well as 
D106 and Y114 that mediate binding of the H1-RBD to target cells [3] are required for  
H1-RBD-mediated receptor interference [36]. The C-terminal domain of the SU contains 
the determinants for HSPG binding [13].  
 
3.4. Relationships between the Neutralizing Domains of the SU and the Residues Involved in Receptor 
Binding 
Of  the  four  neutralizing  regions  of  HTLV-1  SU  described  above,  the  two  N-terminal  regions 
spanning residues 53–75 and 86–107 are located within the predicted HTLV-1 RBD. The second of 
these  contains  residues  that  were  recently  shown  to  be  involved  in  interactions  with  NRP-1  and 
GLUT1 (Figures 1 and 3). Located within the minimal neutralizing SU 90–98 epitope are residues that, 
as  described  above,  mediate  direct  binding  of  the  SU  to  NRP-1:  a  pentapeptide corresponding  to 
residues 90–94 was shown to block both the binding to, and infection of, cells by HTLV-1, and to be 
capable of directly binding to NRP-1 [17].The arginine residue within this motif is the same residue 
(R94) shown in early studies to be important for cell-cell transmission of the virus [44]. The 86–107 Viruses 2011, 3                         
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region also encodes one of the two residues shown to be involved in GLUT1 binding (D106); the other 
residue, Y114, is very close to this region [3]. The importance of these three residues for receptor 
interactions is also supported by observations that expression of an SU fragment corresponding to the 
H1-RBD (aa 1–215) in target cells reduced the titer of HTLV-1 Env-pseudotyped viruses, presumably 
by receptor interference, but that H1-RBD carrying a mutation in R94, D106, or Y114 did not [36]. 
HTLV-1  is  a  member  of  the  deltaretrovirus  family  that  includes  the  closely  related  primate  
T-lymphotropic viruses (PTLVs, see below)  and the more distantly related bovine leukemia virus 
(BLV).  A  structural  model  for  the  SU  of  bovine  leukemia  virus,  which  shares  36%  identity  in  
amino acid sequence with the HTLV-1 SU, was previously generated. This model predicted that the aa 
97–106 region of the BLV SU, which is the homologous to the aa 92–103 region of the HTLV-1 SU, is 
exposed at the surface of the globular structure of the protein [49]. The BLV SU 97–106 region was 
also described earlier as a neutralizing epitope [50]. However, the KPxR motif involved in NRP-1 
binding, which is conserved in all the PTLV SU sequences (see below), is not found in this region of 
BLV, in agreement with early reports that HTLV-1 and BLV use different receptors [51].  
The  C-terminal  neutralizing  region,  aa  287–311,  also  includes  a  region  previously  reported  to 
interact with a component of the proposed HTLV-1 receptor complex. Studies with chimera generated 
between the HTLV-1 SU and the SU of HTLV-2, which does not efficiently bind HSPG, indicate that 
the residues involved in binding HSPGs map to the CTD (aa 215–313). It would be of interest to 
investigate whether deletion in the 287–311 domain reduces HSPG binding, which would explain the 
neutralizing activity of antibodies directed to this part of the SU.  
3.5. Conformational Changes in the HTLV-1 SU 
As mentioned above, attachment to HSPGs is mediated by the C-terminal region of the SU while 
NRP-1 and GLUT1 binding occur via the N-terminal region. This distance between the HSPGs and 
NRP-1/GLUT1 interacting domains are compatible with successive binding events. In contrast, the 
interacting domains for NRP-1 (aa 90–94) or GLUT1 (D106, Y114) are only separated by 16 residues 
(Figure  3).  This  is  consistent  with  the  model  we  proposed,  in  which  the  stable  SU  binding  to 
HSPG/NRP-1  complexes  triggers  conformational  changes  allowing  the  subsequent  recruitment  of 
GLUT1. In this line, it has been reported that the level of cell surface GLUT1 does not correlate with 
the level of binding of the HTLV-1 viral particles or with full-length HTLV-1 SU [13,19], but does 
correlate with the level of binding of the N-terminal H1-RBD fragment (aa 25–215) [3]. This suggests 
that the isolated H1-RBD (N-terminal domain) may have conformational flexibility which allows it to 
bind to GLUT1 independently of conformational changes triggered in the full length SU by NRP-1 
binding (Figure 3). Since SU are organized as trimers, NRP-1 and GLUT1 could also simultaneously 
bind to distinct monomer within SU trimers, as reported for the HIV-1 SU [52]. This could explain the 
fact that tripartite SU/NRP-1/GLUT1 complexes can be detected in cells [9].  
4. Comparison between HTLV-1 and the other PTLVs 
HTLV-1 is one of a group of deltaretroviruses that infect old world primates and humans, referred 
to as primate T-lymphotropic viruses (PTLVs). The viruses in this group that infect humans (HTLVs) 
are  believed  to  have  originated  from  interspecies  transmission  of  simian  T-lymphotropic  viruses Viruses 2011, 3                         
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(STLVs). To date, the PTLV group includes three human viruses for which a simian counterpart is 
known  (HTLV-1/  STLV-1,  HTLV-2/  STLV-2,  and  HTLV-3/  STLV-3)  as  well  as  two  viruses  
(HTLV-4 and STLV-5) for which no counterpart has yet been identified [53–55]. 
4.1. Difference between HTLV-1 and HTLV-2 
Among the PTLV group, nearly all of the studies performed to date have examined the in vivo 
tropism and receptor usage of HTLV-1 and/or HTLV-2. The nucleotide sequence homology of the 
genomes of these two viruses is approximately 60% [56] and their SU proteins share 65% identity on 
an amino acid level [57] (see Figure 4). The notion that these two viruses share the same receptor is 
based on early observations that target cells first infected with HTLV-1 became resistant to HTLV-2 
infection [51]. However, the in vivo tropism of HTLV-1 and HTLV-2 is not identical. HTLV-1 is 
found primarily in CD4
+ T cells, while HTLV-2 is found primarily in CD8
+ T cells [58]. Moreover, the 
ability of these viruses to transform primary T cells in vitro parallel the in vivo observations: HTLV-1 
preferentially  transforms  CD4
+  T  cells  and  HTLV-2  preferentially  transforms  CD8
+  T  cells  [58]. 
Studies using HTLV-1/HTLV-2 recombinant viruses have mapped this difference to the region of the 
genome encoding Env: HTLV-2 viruses carrying the HTLV-1 Env preferentially transform CD4
+ cells, 
while  HTLV-1  viruses  with  HTLV-2  Env  preferentially  transform  CD8
+  T  cells  [59].  While  this 
difference could be due to steps in the viral life cycle after entry, one explanation for the distinct T-cell 
tropism of HTLV-1 and HTLV-2 could be differences in the receptors the viruses use to enter T cells. 
Both  primary  CD4
+  and  CD8
+  T  cells  up-regulate  NRP-1  upon  activation  [60],  consistent  with 
previous reports that HTLV-1 and HTLV-2 bind to activated, but not naïve, T cells [61,62]. Moreover, 
reducing  levels  of  NRP-1  has  been  shown  to  reduce  the  titer  of  both  HTLV-1  and  HTLV-2  
Env-pseudotyped viruses [9]. In contrast, major differences in respect to HSPG and GLUT1 usage 
have  been  reported.  Removal  of  HSPGs  have  been  shown  to  dramatically  reduce  binding  of  the 
HTLV-1, but not HTLV-2, full-length SU to target cells [13]. It was also observed that activated 
primary CD4
+ or CD8
+ T lymphocytes have a reciprocal phenotype in regards to the cell surface 
expression of HSPG and GLUT1, with a high HSPG/low GLUT1 phenotype for activated CD4
+ T 
cells and a low HSPG/high GLUT1 for activated CD8
+ T cells. Moreover, an increase in HTLV-1 but 
not HTLV-2 particle internalization was observed upon overexpression of HSPG in CD8
+ T cells while 
transfection  of  GLUT1  in  a  CD4
+  T  cell  line  only  enhanced  the  internalization  of  the  HTLV-2  
particle [13]. Hence, at least in T cells, HTLV-1 and HTLV-2 do not appear to use the exact same 
receptor  complex,  with  HTLV-2  being  more  dependent  on  the  level  of  GLUT1  and  HTLV-1  on 
HSPGs. However, HTLV-1 and HTLV-2 appear to both interact with NRP-1 and GLUT1, explaining 
why they belong to the same receptor interference group [51].  
The three KPxR residues of the HTLV-1 SU that mediate direct binding to NRP-1 (K91, P92 and 
R94) and the two residues involved in GLUT1 binding (D106 and Y114) are conserved between the 
HTLV-1 and HTLV-2 SU [17,63] (Figure 4). Moreover, R90 of HTLV-2, which is the equivalent of 
R94 of HTLV-1, has been shown to be critical for HTLV-2 infectivity [57]. These findings are fully 
consistent with the notion that HTLV-1 and HTLV-2 both use NRP-1 and GLUT1 during entry.  
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Figure  4.  Alignment  of  the  amino  acid  sequence  of  the  HTLV-1  RBD  with  the 
corresponding regions of the HTLV-2, HTLV-3 and HTLV-4 SU. The KKPNR motif of 
HTLV-1 that mediates direct binding to NRP-1 is boxed and the D106 and Y114 residues 
that mediate binding to GLUT1 are indicated by arrows. The alignment was performed 
with the Clustal W program using the following accession numbers: HTLV-1: Genbank 
AAC82582;  HTLV-2:  GenBank  M10060;  HTLV-3:  GenBank  EU649782  and  
HTVL-4: NCBI NC_011800. An asterisk indicates identical residues, a colon indicates 
conserved substitutions and a period indicates semiconserved substitutions.  
 
4.2. Receptor Usage of Other PTLV 
HTLV-1 and its simian counterpart STLV-1 are highly related viruses which can share up to 98% 
nucleotide sequence homology [64]. The entire SU sequences of HTLV-1 and STLV-1 are highly 
conserved and notably, the aforementioned residues K91, P92, D106 and Y114 are identical between a 
number of HTLV-1 and STLV-1 isolates [65]. This strongly suggests that like HTLV-1, STLV-1 uses 
HSPG, NRP-1 and GLUT1 as entry receptors. High homology between HTLV-2 and STLV-2 isolates 
[66] may similarly indicate that the human and simian type 2 also share the same entry mechanism. 
The  HTLV-3  genome  has  been  sequenced  [67]  and  the  primary  amino  acid  sequences  of  the  
HTLV-1, HTLV-2 and HTLV-3 Env have been compared [63]. Interestingly, although the KKPNR 
sequence is not strictly conserved in the HTLV-3 SU, the three residues in the KPxR motif shown to 
be critical for binding to NRP-1 are present in HTLV-3. Moreover, the D106 and Y114 residues 
important for GLUT1 binding are also strictly conserved between the HTLV-1, HTLV-2 and HTLV-3 
sequences (Figure 4). The only functional studies with the HTLV-3 Env reported to date revealed that, 
unlike HTLV-1 and HTLV-2, the HTLV-3 SU can bind to primary resting CD4
+ T cells that do not 
express detectable levels of HSPG, NRP-1 or GLUT1 [63]. Blocking interactions with either HSPGs 
or NRP-1 reduced the level of binding of HTLV-3 SU and the titer of HTLV-3 Env-pseudotyped 
viruses, but the effect of blocking these interactions was less dramatic than for HTLV-1. It was also 
reported  that,  as  for  HTLV-1,  the  level  of  GLUT1  correlates  with  the  titer  of  HTLV-3  
Env-pseudotyped  virus  but  not  with  the  level  of  binding  of  the  HTLV-3  SU  [63].  These  finding 
suggest that as for HTLV-1, HSPG and NRP-1 may participate in the initial binding step and GLUT1 
in the final fusion step of the HTLV-3 entry process. However, other molecules expressed by resting T Viruses 2011, 3                         
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cells appear to be also involved, that presumably can substitute for HSPG and/or NRP-1 during the 
initial stages of binding. 
The nucleotide sequence of the env gene is not yet available for STLV-5 but the sequence for one 
HTLV-4 isolate has been reported (accession NC_011800.1). Examination of this sequence reveals 
that both the KPxR motif and D106 and Y114 of the HTLV-1 SU are conserved in the amino acid 
sequence of the HTLV-4 SU (Figure 4), suggesting that HTLV-4 may also use NRP-1 and GLUT1 as 
entry receptors.  
5. Conclusions 
The functional domains of the HTLV-1 SU were extensively studied long before the identification 
of the cellular receptors. These earlier studies on Env and recent work on the receptors now converge 
to identify the N-terminal domain (NRP-1 and GLUT1 binding) and the C-terminal domain (HSPG 
binding)  of  the  HTLV-1  SU  as  critical  determinants  for  HTLV-1  entry.  Analysis  of  the  primary 
sequence of other members of the PTLV family predicts that some members may also use NRP-1 and 
GLUT1 as entry receptors, but may differ from HTLV-1 in HSPG usage. Further studies are clearly 
needed to better define the receptor complex used by each PTLV member and understand the impact 
of virus/receptor interactions on the in vivo tropism and infection by HTLV-1 and the other PTLVs.  
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